colorectal-cancer

New synthetic compounds kill colon cancer cells via multiple mechanisms including HDAC inhibition.

New sulfonamide-Schiff base compounds (3a-d) showed significant anticancer activity against DLD-1 and HT-29 CRC cell lines with no toxicity to normal CCD-18Co cells. Compound 3c was most potent in DLD-1 (IC50=3.94 µM) and 3b in HT-29 (IC50=3.26 µM). Multi-mechanism activity: apoptosis induction,…

Dan Manning

Dan Manning

— 1 min read
Share
New synthetic compounds kill colon cancer cells via multiple mechanisms including HDAC inhibition.

New synthetic compounds kill colon cancer cells via multiple mechanisms including HDAC inhibition.

New sulfonamide-Schiff base compounds (3a-d) showed significant anticancer activity against DLD-1 and HT-29 CRC cell lines with no toxicity to normal CCD-18Co cells. Compound 3c was most potent in DLD-1 (IC50=3.94 µM) and 3b in HT-29 (IC50=3.26 µM). Multi-mechanism activity: apoptosis induction, HDAC inhibition (3d: 69% in HT-29), antioxidant induction, and p38/MAPK activation.

Key Findings

  • Compound 3c IC50=3.94 µM in DLD-1; compound 3b IC50=3.26 µM in HT-29
  • No toxicity to normal CCD-18Co colon cells
  • Multi-mechanism activity: apoptosis, HDAC inhibition, antioxidant effects, p38/MAPK activation
  • Compound 3d: 69% HDAC inhibition in HT-29 cells
  • p38/MAPK activation and ERK1 downregulation as key signaling mechanism

Implications

Multi-mechanism activity profile makes these early-stage candidates interesting for CRC drug development. HDAC inhibitory activity is notably valuable.

Caveats

In vitro cell line study; abstract-only. Results require in vivo validation. Multi-mechanism activity may create off-target effects in vivo.

Source: Archiv der Pharmazie — 2026-04-01

Read more